On Monday, Alembic Pharmaceuticals saw a surge in its stock prices after the USFDA greenlit its Diltiazem Hydrochloride Tablets, a crucial treatment for high blood pressure and angina. This pivotal approval brings the company’s total USFDA ANDA approvals to an impressive 230, highlighting its strong position in the pharmaceutical market.
Kaynes shares plunge 43% from October peak. Is a tactical rebound on the cards or more pain ahead?
Kaynes has plunged 43.5% from its October peak, with Friday’s 12.5% drop marking the steepest single-day decline. Momentum indicators remain bearish, signaling a risk of